Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 15

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 15
---
,103 |   |     |       |  207,959 |   |     |             |  225,308 |   |
| Accumulated other comprehensive loss                                                                                                                                                                                                  |     |                |     (610 | ) |     |       |     (610 | ) |     |             |     (610 | ) |
| Accumulated deficit                                                                                                                                                                                                                   |     |                | (172,843 | ) |     |       | (172,843 | ) |     |             | (172,843 | ) |
| Total stockholder’s equity                                                                                                                                                                                                            |     |                |   29,673 |   |     |       |   34,530 |   |     |             |   51,882 |   |
| Total liabilities, common stock and stockholders’ equity                                                                                                                                                                              |     | $              |   37,801 |   |     | $     |   42,658 |   |     | $           |   60,010 |   |

The calculation in the table
above excludes:

| ● | 7,303,307 shares of our common stock issuable upon the exercise                                                                                
 of outstanding stock options as of March 31, 2025, at a weighted average exercise price of $8.28 per share, 5,124,039 of which are exercisable 
 at a weighted average exercise price of $8.71 per share;                                                                                       |

| ● | 3,944,138 shares of our common stock issuable upon the exercise                                       
 of outstanding warrants as of March 31, 2025 at a weighted average exercise price of $7.75 per share; |

| ● | 2,521,243 additional shares of our common stock available for future issuance under our amended and restated INmune Bio Inc. 2021 stock incentive plan; and                                                     |
| ● | 654,847 shares of our common stock sold subsequent to March 31, 2025 pursuant to our “at-the-market” sales agreement with RBC Capital Markets LLC and BTIG, LLC, at a weighted average price of $7.42 per share |

<div align='center'>S-9

DESCRIPTION OF SECURITIES WE ARE OFFERING</div>

Common Stock

We are authorized to issue
200,000,000 shares of common stock, $0.001 par value per share. As of the date of this prospectus, there are 23,585,258shares of common stock issued and